Mutations in serines 15 and 20 of human p53 impair its apoptotic activity
- PMID: 10359526
- DOI: 10.1038/sj.onc.1202656
Mutations in serines 15 and 20 of human p53 impair its apoptotic activity
Abstract
Phosphorylation of the p53 tumor suppressor protein is likely to play an important role in regulating its activity. To study the regulatory role of potential phosphorylation sites within the N-terminal transactivation domain of human p53 (hp53), a series of p53 serine mutants were evaluated for transcriptional transactivation and sequence specific DNA binding. The role of these mutations in regulating p53-mediated growth suppression and programmed cell death was examined. This mutational analysis comprised serine residues located at positions 6, 9, 15, 20, 33 and 37 of human p53. Substitution of serine for alanine, either at individual residues or at all six residues together, did not affect the suppression of cell growth and cell transformation, or the ability to bind DNA specifically and to transactivate different promoters, nor did it alter p53 expression. However, the ability of p53 to induce apoptosis was impaired by specific serine substitutions. Mutations in all six N-terminal serines together reduced the apoptotic activity of p53 in H1299 cells by 50%. Analysis of individual mutants revealed that mutations in serine 15 and 20 are primarily responsible for this impairment. Our results suggest that these serines play a role in the regulation of p53-mediated apoptosis.
Similar articles
-
Serine phosphorylation in the NH2 terminus of p53 facilitates transactivation.Cancer Res. 1995 Jun 1;55(11):2410-7. Cancer Res. 1995. PMID: 7757994
-
A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.Oncogene. 2000 Oct 19;19(44):5098-105. doi: 10.1038/sj.onc.1203848. Oncogene. 2000. PMID: 11042698
-
Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.Oncogene. 2005 Nov 10;24(49):7355-68. doi: 10.1038/sj.onc.1208902. Oncogene. 2005. PMID: 16027730
-
Signaling to p53: breaking the posttranslational modification code.Pathol Biol (Paris). 2000 Apr;48(3):227-45. Pathol Biol (Paris). 2000. PMID: 10858956 Review.
-
The Transactivation Domains of the p53 Protein.Cold Spring Harb Perspect Med. 2017 Jan 3;7(1):a026047. doi: 10.1101/cshperspect.a026047. Cold Spring Harb Perspect Med. 2017. PMID: 27864306 Free PMC article. Review.
Cited by
-
Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1645-8. doi: 10.1073/pnas.0334477100. Epub 2003 Jan 27. Proc Natl Acad Sci U S A. 2003. PMID: 12552135 Free PMC article.
-
Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines.Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13009-14. doi: 10.1073/pnas.230445997. Proc Natl Acad Sci U S A. 2000. PMID: 11069295 Free PMC article.
-
Induction and bypass of p53 during productive infection by polyomavirus.J Virol. 2002 Sep;76(18):9526-32. doi: 10.1128/jvi.76.18.9526-9532.2002. J Virol. 2002. PMID: 12186934 Free PMC article.
-
A role for c-Jun N-terminal kinase 1 (JNK1), but not JNK2, in the beta-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neurons.Biochem J. 2003 May 1;371(Pt 3):789-98. doi: 10.1042/BJ20021660. Biochem J. 2003. PMID: 12534344 Free PMC article.
-
Low glucose metabolite 3-phosphoglycerate switches PHGDH from serine synthesis to p53 activation to control cell fate.Cell Res. 2023 Nov;33(11):835-850. doi: 10.1038/s41422-023-00874-4. Epub 2023 Sep 19. Cell Res. 2023. PMID: 37726403 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous